SLC18A2
MOLECULAR TARGETsolute carrier family 18 member A2
SLC18A2 (solute carrier family 18 member A2) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SLC18A2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Reserpine | 2.94 | 18 |
| 2 | Lobeline | 2.83 | 16 |
| 3 | Duloxetine Hydrochloride | 0.69 | 1 |
| 4 | Fluoxetine | 0.69 | 1 |
| 5 | Mianserin | 0.69 | 1 |
| 6 | Oleic Acid | 0.69 | 1 |
| 7 | Sertraline | 0.69 | 1 |
| 8 | Aripiprazole | 0.69 | 1 |
| 9 | Benzethonium Bactericidal cationic quaternary ammonium surfactant used as | 0.69 | 1 |
| 10 | dofetilide | 0.69 | 1 |
| 11 | Ibogaine | 0.69 | 1 |
About SLC18A2 as a Drug Target
SLC18A2 (solute carrier family 18 member A2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented SLC18A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SLC18A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.